AUC

Alliance for Pediatric Device Innovation announces MedTech Color edition of “Make Your Medical Device Pitch For Kids!”™ supporting African American and Hispanic innovators

Retrieved on: 
Tuesday, October 10, 2023
MBA, Interest, Food, AUC, Food and Drug Administration Amendments Act of 2007, Tufts Medical Center, Communication, Mass, Mass General Brigham, Hospital, FDA, Doctor of Philosophy, Marketing, Research, Medtech, Johns Hopkins University, Medical device, Nursing

With the aim of making pediatric medical device innovation more inclusive, organizers are accepting applications for pediatric medical devices from innovators of color who are traditionally underrepresented in the medical device industry.

Key Points: 
  • With the aim of making pediatric medical device innovation more inclusive, organizers are accepting applications for pediatric medical devices from innovators of color who are traditionally underrepresented in the medical device industry.
  • The organization works to advance the representation of people of color in the medical device industry and to nurture the next generation of founders.
  • African American and Hispanic pediatric MedTech innovators,“ said Kwame Ulmer, founder and executive director of MedTech Color.
  • Advancements in pediatric medical devices continue to lag significantly behind those of adults, which is why APDI is focused on helping more pediatric medical device innovations achieve commercialization.

Nucleix Advances Early Lung Cancer Detection Program with Promising Performance Data and Appointment of Chief Scientific Officer

Retrieved on: 
Wednesday, October 11, 2023
Biotechnology, Medical Devices, Hospitals, Health, Oncology, Annual general meeting, Lung cancer, Neoplasm, Biomarker, American College of Chest Physicians, NSCLC, American College, PCR, NGS, DNA, AUC, MPH, Disease, Lung, Patient, Sightline (architecture), National Lung Screening Trial, Cleveland, Liquid biopsy, Cleveland Clinic, Medical imaging

Nucleix , a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced recent updates in its lung cancer detection program for early-stage disease.

Key Points: 
  • Nucleix , a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced recent updates in its lung cancer detection program for early-stage disease.
  • Additionally, the company strengthened its leadership team with the appointment of Mathias Ehrich, M.D., as its chief scientific officer.
  • Earlier this year, the company announced that the Nucleix EpiCheck® Lung Atlas, which utilizes next-generation sequencing (NGS) and is focused on stage I disease, had identified many promising, novel biomarkers for the early detection of lung cancer.
  • “Over the past few months, we’ve made incredible progress on our lung cancer program, having recently premiered data on the Nucleix EpiCheck Lung Atlas and enrolled more than 4,000 patients in the Sightline study,” said Chris Hibberd, chief executive officer of Nucleix.

ASRM ANNOUNCES HISTORIC $5 MILLION ENDOWMENT FROM FERRING PHARMACEUTICALS

Retrieved on: 
Monday, October 16, 2023
Congress, Ferring Pharmaceuticals, Parent, Hospital, MBA, AUC, Hope, Reproductive medicine, Economics, Education, MD, Caregiver, REI, Society, American Society for Reproductive Medicine, Workforce, Growth, Golden Joystick Awards, ASRM, History, Corporate Affairs, Health professional, Infertility, Physician, Nursing, Management

WASHINGTON and PARSIPPANY, N.J., Oct. 16, 2023 /PRNewswire/ -- The American Society for Reproductive Medicine (ASRM) and Ferring Pharmaceuticals today announced a historic $5 million endowment from Ferring to ASRM.  This endowment, the largest in ASRM's nearly 80-year history, will establish the "Ferring Endowment for the Education of Healthcare Professionals in Training," ensuring ASRM's continued legacy as the leading educator for professionals in the field.

Key Points: 
  • WASHINGTON and PARSIPPANY, N.J., Oct. 16, 2023 /PRNewswire/ -- The American Society for Reproductive Medicine (ASRM) and Ferring Pharmaceuticals today announced a historic $5 million endowment from Ferring to ASRM.
  • This endowment, the largest in ASRM's nearly 80-year history, will establish the "Ferring Endowment for the Education of Healthcare Professionals in Training," ensuring ASRM's continued legacy as the leading educator for professionals in the field.
  • We're honored to partner with ASRM to augment their learning opportunities at this important stage of their careers," said Jade Levi Shields, Vice President, Corporate Affairs, Ferring Pharmaceuticals.
  • "ASRM is immensely grateful to Ferring for this generous endowment that will address the longstanding need for more early career training in reproductive medicine.

The AUC Data Science Initiative partners with Mastercard to further drive impact through data science

Retrieved on: 
Monday, October 16, 2023
Partnership, Data science, Multimedia, Historically black colleges and universities, Student, Faculty, Morehouse College, HBCU, AUC, Employment, Education, Workforce, Atlanta University Center, Trustee, 2023 Las Vegas Aces season, Mastercard, Curriculum, Research, Nursing, University

ATLANTA, Oct. 16, 2023 /PRNewswire/ -- The Atlanta University Center (AUC) Data Science Initiative announces the launch of a new partnership with Mastercard at 12:00 PM on October 18th at the AUC Robert W. Woodruff Library. The event will detail the innovative partnership which is supported by a $6.5 million grant from Mastercard to drive the expansion of data science across the nation's Historically Black Colleges and Universities (HBCUs).

Key Points: 
  • ATLANTA, Oct. 16, 2023 /PRNewswire/ -- The Atlanta University Center (AUC) Data Science Initiative announces the launch of a new partnership with Mastercard at 12:00 PM on October 18th at the AUC Robert W. Woodruff Library.
  • Through a $6.5M grant, Mastercard will support the expansion of data science education and research efforts at HBCU's.
  • Dr. Talitha Washington, Ph.D., Director of the AUC Data Science Initiative, will lead collaboration with other HBCUs to create new innovations in curricula and research.
  • Learn more about the AUC Data Science Initiative: https://datascience.aucenter.edu and to attend the Oct 18th Mastercard partnership event: https://tinyurl.com/MastercardDSI
    View original content to download multimedia: https://www.prnewswire.com/news-releases/the-auc-data-science-initiative...

Vesica Health Announces Publication of Study Demonstrating AssureDx Meaningfully Improves Identification of Hematuria Patients at High Risk for Bladder Cancer

Retrieved on: 
Monday, October 9, 2023
OTX1, Probability, AUA, Physician, Department of Urology, University of Virginia, National Capital FreeNet, American Urological Association, TERT, Johns Hopkins University, DNA, Risk, AUC, Capital city, Microhematuria, Urology, Hematuria, Health, HEALTH, Cancer, Carcinoma, TWIST1, Alvin J. Siteman Cancer Center, HRAS, DNA methylation, European Urology, Medical school, Patient, Bladder cancer, FGFR3, Liquid biopsy, Risk assessment, Barnes-Jewish Hospital

The study titled "A Urine-based Genomic Assay Improves Risk Stratification for Patients with High-risk Hematuria Stratified According to the American Urological Association Guidelines" was published in the journal European Urology Oncology.

Key Points: 
  • The study titled "A Urine-based Genomic Assay Improves Risk Stratification for Patients with High-risk Hematuria Stratified According to the American Urological Association Guidelines" was published in the journal European Urology Oncology.
  • The study analyzed a prospectively collected cohort of 838 hematuria subjects previously tested by AssureDx.
  • Subjects were classified into the AUA risk categories for bladder cancer based on their sex, age, and type of hematuria, also known as urothelial carcinoma (UC).
  • "Publication of this pivotal study in a leading international urology journal, demonstrating AssureDx enhances the AUA Guidelines, underscores the importance of the test for risk stratification of hematuria patients and identification of those at increased risk for bladder cancer," stated Christopher Thibodeau, Chief Executive Officer of Vesica Health.

HemoSonics Wins Medical Device Network Excellence Award in Two Categories

Retrieved on: 
Thursday, October 5, 2023
Hospital, Food, AUC, Business, Intelligence, Journal of Cardiothoracic Surgery, Intensive care medicine, Health, Coagulation, Artificial intelligence, FDA, New product development, Trauma, Cartridge, GlobalData, Regulation of tobacco by the U.S. Food and Drug Administration, Patient, Operating, Medical device

DURHAM, N.C., Oct. 5, 2023 /PRNewswire/ -- HemoSonics, a medical device company delivering individualized diagnostic solutions for acute care bleeding and the management of coagulation, announced today that the company has won in both the Product Launch and Business Expansion categories in the 2023 Medical Device Network Excellence Awards. HemoSonics' Quantra Hemostasis System provides comprehensive whole-blood coagulation analysis at the point of care in less than 15 minutes. Clinicians don't need to wait on test results during a serious life-threatening bleeding event, and, as a result, patients receive optimized interventions as quickly as possible and only when needed.

Key Points: 
  • DURHAM, N.C., Oct. 5, 2023 /PRNewswire/ -- HemoSonics , a medical device company delivering individualized diagnostic solutions for acute care bleeding and the management of coagulation, announced today that the company has won in both the Product Launch and Business Expansion categories in the 2023 Medical Device Network Excellence Awards .
  • HemoSonics' Quantra Hemostasis System provides comprehensive whole-blood coagulation analysis at the point of care in less than 15 minutes.
  • The Medical Device Network Excellence Awards is an independent recognition program powered by the business intelligence of GlobalData .
  • HemoSonics also received an innovative technology contract award from Vizient, opening the door for the System to be adopted by hospitals and academic medical centers across the United States.

FROEDTERT HEALTH, WISCONSIN DIAGNOSTIC LABORATORIES AND HEALTHECO LAUNCH ATALAN, A TECHNOLOGY-ENABLED CLINICAL PARTNERSHIP PROVIDING ACCESS TO THE BEST IN LABORATORY MEDICINE

Retrieved on: 
Thursday, October 5, 2023
Laboratory, Diagnosis, Partnership, WDL, Korea Disease Control and Prevention Agency, Death, AUC, Growth, System, Patient, Marie Cassidy, Pharmaceutical industry, Health care

MILWAUKEE, Oct. 5, 2023 /PRNewswire/ -- Froedtert Health, Wisconsin Diagnostic Laboratories (WDL) and HealthEco announced today the launch of Atalan, a technology-enabled clinical partnership providing doctors and medical centers unprecedented access to a vetted network of the nation's foremost clinical laboratories.

Key Points: 
  • MILWAUKEE, Oct. 5, 2023 /PRNewswire/ -- Froedtert Health, Wisconsin Diagnostic Laboratories (WDL) and HealthEco announced today the launch of Atalan , a technology-enabled clinical partnership providing doctors and medical centers unprecedented access to a vetted network of the nation's foremost clinical laboratories.
  • Atalan expands access to high-value laboratory services which will ultimately improve patient diagnostics and care.
  • According to the Centers for Disease Control and Prevention, 70% of today's medical decisions depend on laboratory test results and 14 billion laboratory tests are ordered each year.
  • Yet many patients, particularly those in rural areas, experience barriers to critical laboratory services, limiting their ability to receive the care they need.

New York Blood Center Enterprises Acquires Commercial-Scale Cell & Gene Therapy Development and Manufacturing Facilities from Talaris Therapeutics

Retrieved on: 
Wednesday, October 4, 2023
GMP, Interim, Drug development, AUC, ISO, CMC, Messenger, Cryopreservation, Regenerative medicine, Hospital, Acquisition, MD, Collection, Patient, Blood, Quality control, CCS, ISO 7, Transport, Therapy, Vaccine

NEW YORK and BOSTON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- New York Blood Center Enterprises (NYBCe) and Talaris Therapeutics, Inc. (Nasdaq: TALS) (“Talaris”) announced today NYBCe’s acquisition of commercial-scale cell and gene therapy development and manufacturing facilities, as well as certain technologies and equipment from Talaris in Houston, Texas and Louisville, Kentucky.

Key Points: 
  • NEW YORK and BOSTON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- New York Blood Center Enterprises (NYBCe) and Talaris Therapeutics, Inc. (Nasdaq: TALS) (“Talaris”) announced today NYBCe’s acquisition of commercial-scale cell and gene therapy development and manufacturing facilities, as well as certain technologies and equipment from Talaris in Houston, Texas and Louisville, Kentucky.
  • The acquisition of both locations, combined with NYBCe’s Comprehensive Cell Solutions (CCS) vast cell sourcing and collection network, accelerates the delivery of a fully integrated vein-to-vein cell and gene therapy development and manufacturing solution for the continental United States (US), capable of serving the biopharma industry and large hospital systems.
  • “I am exceptionally pleased with this strategic expansion of our CCS portfolio,” said Christopher D. Hillyer, MD, President and Chief Executive Officer at NYBCe, “which now allows NYBCe to have in-house start-to-finish cell and gene therapy, and regenerative medicine, development and manufacturing capabilities.
  • ft. of analytical and process development capacity enhancing NYBCe’s expertise in broad analytical methodologies across cell types, viral vectors, mRNA, and gene expression analysis.

Nexcella Announces Complete Response in 9th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial at IMS 20th Annual Meeting

Retrieved on: 
Tuesday, October 3, 2023
Travel, Hematopoietic stem cell transplantation, AUC, AL amyloidosis, MRD, Hadassah Medical Center, AL, Patient, IMS, Amyloidosis, LOS, Daratumumab, BCMA, Pharmaceutical industry, Immunotherapy

LOS ANGELES, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), today announced presentation of additional AL Amyloidosis clinical data from its Phase 1b/2a NEXICART-1 (NCT04720313) study of novel, autologous, BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy, NXC-201, at an oral presentation at the 20th International Myeloma Society Annual (IMS) Meeting being held in Athens, Greece on September 27-30 2023. One new patient and additional follow-up data from an additional 8 patients (9 total) are included in this update. All patients were DARZALEX® (daratumumab) combination therapy relapsed/refractory and experienced a median of 6 earlier treatments that failed to stop worsening of disease (lines of therapy) prior to receiving NXC-201.

Key Points: 
  • One new patient and additional follow-up data from an additional 8 patients (9 total) are included in this update.
  • “NXC-201’s 100% response rate in relapsed/refractory AL amyloidosis patients, including t(11;14) and cardiac involved, indicates a potential broad mechanism of action.
  • Median follow-up was 7.3 months (range: 2.5 – 16.5 months) as of the September 20, 2023 data cutoff.
  • Data highlights:
    Best responder had a duration of response of 19.2 months as of the data cutoff of September 20, 2023, with response ongoing
    For the 7 relapsed/refractory AL Amyloidosis patients with cardiac involvement:
    4 patients with t(11;14) relapsed/refractory AL Amyloidosis:
    The 20th IMS AL Amyloidosis presentation can be accessed on the Nexcella corporate website at this link: https://nexcella.com/publications/
    20th International Myeloma Society Annual Meeting, Athens, Greece

Immix Biopharma Announces Complete Response in 9th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial at IMS 20th Annual Meeting

Retrieved on: 
Tuesday, October 3, 2023
Travel, Hematopoietic stem cell transplantation, AUC, AL amyloidosis, Thirty Days, MRD, Hadassah Medical Center, AL, Patient, IMS, Amyloidosis, LOS, Daratumumab, BCMA, Pharmaceutical industry, Hospital, Immunotherapy

One new patient and additional follow-up data from an additional 8 patients (9 total) are included in this update.

Key Points: 
  • One new patient and additional follow-up data from an additional 8 patients (9 total) are included in this update.
  • “NXC-201’s 100% response rate in relapsed/refractory AL amyloidosis patients, including t(11;14) and cardiac involved, indicates a potential broad mechanism of action.
  • Median follow-up was 7.3 months (range: 2.5 – 16.5 months) as of the September 20, 2023 data cutoff.
  • Data highlights:
    Best responder had a duration of response of 19.2 months as of the data cutoff of September 20, 2023, with response ongoing
    For the 7 relapsed/refractory AL Amyloidosis patients with cardiac involvement:
    4 patients with t(11;14) relapsed/refractory AL Amyloidosis:
    The 20th IMS AL Amyloidosis presentation can be accessed on the ImmixBio corporate website at this link: https://immixbio.com/pipeline/#publications
    20th International Myeloma Society Annual Meeting, Athens, Greece